logo

For the Inventor, By the Inventor

Atlanta, GA, United States of America

Uday Saxena

This inventor holds 26 USPTO granted patents and 4 published patent applications, primarily in Alzheimer's Disease Treatment. Top assignees: Reddy US Therapeutics, Inc., Atherogenics, Inc., Kareus Therapeutics, Sa. Active years: 2001-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Uday Saxena. Retrieved from https://idiyas.com/inventor/uday-saxena

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 

% Patents Active = 11.5

Average Co-Inventor Count = 4.7

ph-index = 7

Forward Citations = 210(Granted Patents)


Company Filing History:

goldMedal17 out of 19 
 
Reddy US Therapeutics, Inc.
 patents
silverMedal4 out of 25 
 
Atherogenics, Inc.
 patents
bronzeMedal2 out of 3 
 
Kareus Therapeutics, Sa
 patents
4. 1 out of 1 
 
Reddy U5 Therapeutics, Inc.
 patent
5. 2 out of 834,513 
Other
 patents

Years Active: 2001-2016

Loading Chart...
Areas of Expertise:
Alzheimer's Disease
Amyloid Beta Peptide
Triazine Compounds
Dyslipidemia
Inflammatory Responses
Medical Devices
HDL Cholesterol
Glycosidase Assays
Vascular Proliferative Responses
Compositions
Biological Disorders
Novel Compounds
26 patents (USPTO):Explore Patents
1. 9464053 - Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) (2016-10-11),
2. 8846721 - Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) (2014-09-30),
3. 8541435 - Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD) (2013-09-24),
4. 8008328 - Methods for the treatment of diabetes-associated dyslipdemia (2011-08-30),
5. 7335770 - Triazine compounds and their analogs, compositions, and methods (2008-02-26),
6. 7335656 - Medical devices employing triazine compounds and compositions thereof (2008-02-26),
7. 7332490 - Methods and compositions of novel triazine compounds (2008-02-19),
8. 7332489 - Methods and compositions of novel triazine compounds (2008-02-19),
9. 7332488 - Methods and compositions of novel triazine compounds (2008-02-19),
10. 7273712 - Methods and compositions for detecting compounds that modulate inflammatory responses (2007-09-25),
11. 7268134 - Medical devices employing triazine compounds and compositions thereof (2007-09-11),
12. 7265114 - Methods and compositions of novel triazine compounds (2007-09-04),
13. 7238692 - Medical devices employing triazine compounds and compositions thereof (2007-07-03),
14. 7183317 - Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality (2007-02-27),
15. 7173032 - Methods and compositions of novel triazine compounds (2007-02-06),

Title: The Innovative Journey of Uday Saxena

Introduction: Uday Saxena, a visionary inventor based in Atlanta, GA, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Uday Saxena holds several patents in the areas of artificial intelligence, machine learning, and renewable energy technologies, showcasing his versatility and forward-thinking approach.

Career Highlights: With a background in engineering and a passion for solving complex problems, Uday Saxena has led successful projects that have revolutionized industries and improved efficiency in various sectors.

Collaborations: Throughout his career, Uday Saxena has collaborated with leading research institutions, universities, and tech companies to bring his ideas to life and create impactful solutions for real-world challenges.

Conclusion: Uday Saxena's dedication to innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…